Inclusion Criteria:

- Adults with documented diagnosis of CLL based on the modified IWCLL updated NCI-WG
guidelines (Hallek, 2008)

- At least PR according to the revised 2008 NCI-WG CLL criteria, within 3 months of
the response assessment after the last dose of 2nd/3rd line treatment

- The anti-leukemic treatment before study entry should have been at least 3 months or
3 cycles

- ECOG Performance Status of 0-2

- Signed written informed consent prior to performing any study-specific procedures

Exclusion Criteria:

- Known primary or secondary fludarabine-refractory subjects, defined as treatment
failure (failure to achieve a CR or PR) or disease progression within 6 months

- Prior maintenance therapy

- Known transformation of CLL (eg.Richter's transformation), prolymphocytic leukemia
(PLL), or CNS involvement of CLL

- Active Autoimmune hemolytic anemia (AIHA) requiring treatment except if in the
opinion of the investigator and medical monitor it is thought not to affect the
subject's safety, the conduct of the study or the interpretation of the data

- Previous autologous or allogeneic stem cell transplantation

- Chronic or current active infectious disease requiring systemic antibiotics,
antifungal, or antiviral treatment such as, but not limited to chronic renal
infection, chronic chest infection with bronchiectasis, tuberculosis and active
Hepatitis B or C

- Other past or current malignancy (with the exception of basal cell carcinoma or the
skin or in situ carcinoma of the cervix or breasts) unless the tumor was successfully
treated with curative intent at least 2 years prior to trial entry except if in the
opinion of the investigator and medical monitor it is thought not to affect the
subject's safety, the conduct of the study or the interpretation of the data

- Clinically significant cardiac disease, including unstable angina, acute myocardial
infarction within 6 months prior to screening, congestive heart failure, and
arrhythmia requiring therapy, with the exception of exta systoles or minor conduction
abnormalities except if in the opinion of the investigator and medical monitor it is
thought not to affect the subject's safety, the conduct of the study or the
interpretation of the data

- History of significant cerebrovascular disease or event with symptoms or sequelae

- Significant concurrent, uncontrolled medical condition that in the opinion of the
investigator or GSK medical monitor contraindicates participation in this study

- Other anti-leukemic use of medications including glucocorticoids

- Known HIV positive

- Screening laboratory values: platelets <50 x 109/L, neutrophils<1.0 x 109/L,
Creatinine > 1.5 X upper normal limit (unless normal creatinine clearance), total
bilirubin >1.5 X upper normal limit, ALT >2.5 X upper normal limit (unless due to
liver involvement of CLL), alkaline phosphase > 2.5 X upper normal limit

- Known or suspected hypersensitivity to ofatumumab that in the opinion of the
investigator or medical monitor contraindicates study participation

- Subjects who have received treatment with any non-marketed drug substance or
experimental therapy within 5-terminal half-lives or 4 weeks whichever is longer
prior to first dose of study medication or currently participating in any other
interventional clinical study Note: Participation in any other interventional
clinical study after disease progression during post PD follow-up is permitted

- Lactating women, women with a positive pregnancy test at Visit 1 or women (of
childbearing potential) as well as men with partners of childbearing potential, who
are not willing to use adequate contraception from study start through one year
following last ofatumumab dose. Adequate contraception is defined as abstinence,
oral hormonal birth control, implants of levonorgestrel, estrogenic vaginal ring,
percutaneous contraceptive patches, intrauterine device, and male partner
sterilization if male partner is sole partner for that subject. For females in the
USA, the use of a double barrier method is also considered adequate (condom or
occlusive cap plus spermicidal agent).